Deupirfenidone is under clinical development by Puretech Health and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Deupirfenidone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deupirfenidone (SD-560, LYT-100) is under development for the treatment of lymphedema and long COVID-19 (PACS) patients with respiratory complications including inflammation, fibrosis, pneumonia and focal segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases (PF-ILDs). It was under development for the treatment of systemic sclerosis and other orphan diseases. The drug candidate is administered through oral route. The drug candidate is an analogue of deuterium-substituted pirfenidone and is developed based on Deuteration technology. It is a new chemical entity.
Puretech Health overview
Puretech Health (Puretech) formerly PureTech Ventures, is a biotherapeutics company that discovers, develops, and commercializes drugs to treat lung dysfunction, immuno-oncology, lymphatic, neurological, and neuropsychological disorders. The company is investigating pipeline programs such as LYT-100 (deupirfenidone), targeting inflammation and fibrosis, lymphedema, and SARS-CoV-2 respiratory problems; LYT-200, a human monoclonal antibody for the treatment of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA); and LYT-210, a gamma delta-1 T cell receptor against solid tumors. It is also evaluating LYT-300, oral allopregnanolone for neurological indications. Puretech works in collaboration with pharmaceutical and biotechnology companies to develop its products. Puretech is headquartered in Boston, Massachusetts, the US.
For a complete picture of Deupirfenidone’s drug-specific PTSR and LoA scores, buy the report here.